TORONTO, March 17, 2021 /CNW/ – atai Life Sciences AG (“ atai“), announced today that it entered into a securities purchase agreement (the “Subscription Agreement“) with IntelGenx Technologies Corp. (“IntelGenx“) pursuant to which atai agreed to purchase 37,300,000 newly issued common stock units of IntelGenx (“Units“) for aggregate gross proceeds of US$12,346,300 or approximately US$0.


Previous articlePsychedelic Capitalism and Other Myths: Is the Joke On Us?
Next articleTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics